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Background: There is a need for better tools to evaluate new or repurposed TB drugs. The whole blood
bactericidal activity (WBA) assay has been advocated for this purpose. We investigated whether transcriptional
responses in the WBA assay resemble TB responses in vivo, and whether the approach might additionally reveal
mechanisms of action.
Results: 1422 of 1798 (79%) of differentially expressed genes in WBA incubated with the standard combination of
rifampicin, isoniazid, pyrazinamide and ethambutol were also expressed in sputum (P < 0.0001) obtained from
patients taking the same combination of drugs; these comprised well-established treatment-response genes. Gene
expression profiles in WBA incubated with the standard drugs individually, or with moxifloxacin or faropenem (with
amoxicillin and clavulanic acid) clustered by individual drug exposure. Distinct pathways were detected for
individual drugs, although only with isoniazid did these relate to known mechanisms of drug action.
Conclusions: Substantial agreement between whole blood cultures and sputum and the ability to differentiate
individual drugs suggest that transcriptomics may add value to the whole blood assay for evaluating new TB drugs.
Keywords: Tuberculosis, Gene expression, Transcriptome, Mechanism of action, Anti-tuberculosis drugs, Whole
blood assay, Microarray, FaropenemBackground
Previous studies have examined the effect of anti-
tuberculous drugs on the Mycobacterium tuberculosis
(Mtb) transcriptome in sputum [1, 2], broth cultures [3–
5], and a macrophage model [4]. Mtb transcriptional pro-
filing has been shown to be able to decipher drug mechan-
ism of action, such as genes related to mycolic acid and
fatty acid biosynthesis (FAS-II) when exposed to isoniazid
[3–5]. One small longitudinal study delineated the
changes in gene expression in the sputum during the© The Author(s). 2020 Open Access This artic
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possible that this approach may add value to traditional
biomarker outcomes that are known to have limited value
in predicting sterilizing activity in TB [6, 7]. However, fur-
ther work is needed to understand transcriptome re-
sponses to individual drugs and drug combinations and
whether they have ability to differentiate between drugs.
The whole blood bactericidal activity (WBA) model
has been used as an early clinical screening platform for
novel TB drugs/regimens prior to testing in clinical tri-
als. It is an ex vivo model that measures the bactericidal
activity of one or more drugs combined with host im-
mune responses. This has been applied to testing a var-
iety of established and novel antibacterial drugs and,
more recently, putative host-directed therapies [8–15].
The objectives of this study were to determine if Mtb
transcriptome responses in the WBA model could reflectle is licensed under a Creative Commons Attribution 4.0 International License,
ution and reproduction in any medium or format, as long as you give
the source, provide a link to the Creative Commons licence, and indicate if
d party material in this article are included in the article's Creative Commons
line to the material. If material is not included in the article's Creative Commons
d by statutory regulation or exceeds the permitted use, you will need to obtain
. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
tion waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
rwise stated in a credit line to the data.
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treatment and whether this approach could identify
unique transcriptome responses associated with individ-
ual anti-tuberculous drugs.
Results
There was evidence of strong bactericidal activity in the whole
blood assay with isoniazid, rifampicin, and moxifloxacin
tested individually and with isoniazid, rifampicin, pyrazina-
mide and ethambutol tested in combination (− 1.62, − 2.74,
− 1.92 and 3.49 Δlog CFU respectively), whereas pyrazina-
mide, ethambutol and faropenem used individually had no
substantive evidence of bactericidal activity over the 72-h in-
cubation period (Supplementary Figure 1).
In the whole blood assays set-up for gene expression
analysis, microarray signals were obtained from all ex-
perimental conditions and no sample outliers were de-
tected after RNA normalization.
Compared to drug-free broth cultures, there were
1755 differentially expressed genes (DEG) in drug-free
whole blood cultures;1798 DEG in whole-blood cultures
containing the standard 4-drug combination (1541, 86%
overlapping with drug-free whole blood cultures); 1701
DEG in sputum from TB patients taking the same stand-
ard combination (Supplementary Table 1 and 2 respect-
ively). Of the 1798 DEG in whole-blood cultures with
standard drugs, 1422 (79%) were also expressed in spu-
tum (p < 0.00001), all but one in the same direction in
the two assay conditions (267 up- and 1154 down-
regulated); of these overlap genes, 1317 (90%) were also
expressed in the whole blood cultures without drugs.
The DEG in whole blood cultures with standard drugs
included genes from pathways known to be affected by
standard TB treatment, such as DosR and KstR regulon
genes upregulated, and multiple ATP synthesis, fatty
acid synthesis genes downregulated (Table 1) [1, 2]. The
376 DEG in the whole blood cultures that were not
found in sputum, and the 279 DEG in sputum but not
found in the whole blood cultures had similar GeneTable 1 Differentially expressed genes in whole blood assay with st
pathways (as reported in Honeyborne et al) [1]
Gene pathway DEGs found in whole blood assay with sta
DosR regulon nrdZ
KstR regulon Rv1628c
Triacylglycerol synthesis Rv3087
Aerobic respiration cta/C/D/E; nuoD/G/K; qcRA/B/C
ATP synthesis atpA/B/C/D/E/F/G
Citric acid cycle gltA2; Rv0247c; Rv0248c; sucC
Fatty acid synthesis fabD; fabG1; fas; kasA/B
Mycolic acid biosynthesis cmaA2; fadD32; mmaA3/A4; pcaA; korA
Ribosome biosynthesis rplx11; rpmX5; rpoA/B/C; rpsAx13Ontology Molecular pathways; the majority (70–71%)
were associated with the catalytic activity pathway (Sup-
plementary Table 3).
Analysis of the gene expression profiles obtained from
cultures performed with the six individual drugs found no
evidence of clustering by volunteer blood sample (AU ≥
95% for clustering by individual antibiotics; Fig. 1; Supple-
mentary Figure 2). Analysis of the gene clusters identified
several clusters that were associated with pathways related
to common modes of drug action (membrane-related pro-
cesses; nucleotide-binding, ATP-binding and lipid metab-
olism; and oxidoreductase; Fig. 2).
Analysis of DEG in whole blood cultures with individ-
ual drugs but not in the drug-free cultures (both relative
to broth cultures), found genes that were that were both
unique for the specific drugs and genes that overlapped
with other individual drugs (Fig. 3). The overall drug-
related gene expression profile (including the genes that
were differentially expressed with other drugs) for each
of the six individual drug whole-blood cultures had a
median of 239 (range 201 to 251) differentially expressed
genes (Fig. 3; Supplementary Table 4). The unique drug-
related gene expression profile (excluding the genes that
were differentially expressed with other drugs) for each
individual drug had a median of 44 (range 39 to 58)
DEGs (Fig. 3; Supplementary Table 5).
Analysis of pathways associated with the overall drug-
related gene expression profile identified significantly
enriched pathways for all individual drugs (Supplemen-
tary Table 6). Of the 19 significant pathways identified
for isoniazid cultures, 8 were related to the known
mechanisms of action of isoniazid including fatty-acyl-
CoA binding, flavin adenine dinucleotide and acyl-CoA
dehydrogenase activity. None of the pathways identified
with other drugs appeared to be associated with known
mechanisms of drug action. Analysis of pathways using
the unique drug-related expression profile identified
pathways for all individual drugs except faropenem and
moxifloxacin; Supplementary Table 7). Of the 6 pathwaysandard combination treatment that are found in known TB
ndard combination treatment Direction of differential expression
Up
Up
Up
Down
Down
Down
Down
Down
Down
Fig. 1 Flow chart for transcriptional analyses. DEG: Differentially expressed genes. HZRE: combination of four standard anti-tuberculosis drugs
isoniazid, pyrazinamide, rifampicin and ethambutol
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ism of action (all were found in the 8 pathways identified
with the overall drug-related gene-expression profile).
Again, none of the pathways with the other drugs were
plausibly related to mechanism of action.
Analysis of individual genes from the unique drug-
related expression profiles identified genes directly asso-
ciated with mechanism of actions of isoniazid (e.g.
mycolic acid biosynthesis pathway), rifampicin (ribonu-
cleoside binding); or indirectly related, ethambutol
(membrane components) [16]; moxifloxacin (DNA-bind-
ing, gyrA/B) [17]; pyrazinamide (active form of pyrazi-
noic acid, PanD) [18] and faropenem (beta-lactam-
targeted efflux pumps; Supplementary Table 8) [19].
Discussion
Our finding that the gene expression signature from the
combination of standard TB drugs (rifampicin, isoniazid,
pyrazinamide and ethambutol) in whole blood culture
was similar to the in vivo gene expression profile in spu-
tum obtained from patients taking the same standard
combination of drugs for a period of one to two weeks
(and with the profile obtained in another study of spu-
tum gene expression) [1, 2] lends initial support to the
validity of the adapted WBA model to assess transcrip-
tome responses to TB drugs. The advantage of evaluat-
ing bacterial transcriptome responses in the whole bloodassay is that the assay includes human immune cells and
this may account in part for the similarity with the bac-
terial transcriptome in sputum (where bacilli have also
been exposed to the lung immune response) as well as
the overlap with the genes expressed in the blood cul-
tures without drugs (with all conditions differing qualita-
tively from cell-free broth culture). Furthermore, the
DEG in whole blood culture included changes in path-
ways known to be affected by combination TB therapy,
including those that are suppressed (e.g. aerobic respir-
ation, citric acid cycle and ATP synthesis) and those that
are induced (e.g. DosR) [1, 2]. This suggests that Mtb
also responses to drugs in the whole blood environment
by reducing energy levels and activating metabolic path-
ways associated with anaerobic conditions (e.g. DosR
regulon) [20] to survive. Some differences in gene ex-
pression profile would be expected from the different
assay conditions, including the difference in immune mi-
lieu, but even the genes that were unique between spu-
tum and whole blood still shared similar molecular
pathways. We cannot say whether the degree of overlap
with sputum DEG is any greater than we might have
seen had we done the experiment with standard TB
drugs in broth culture rather than the WBA model, al-
though the immune contribution (above) suggests that it
may be; no published studies have compared gene ex-
pression responses to standard TB drugs in both broth
Fig. 2 Heatmap of gene profiles obtained from cultures with individual anti-TB drugs. The dendrograms are generated by hierarchical clustering
using Euclidean distance and complete linkage method. Each column represents a separate whole blood assay (n = 24; 6 individual drugs, each
tested with blood from 4 individual volunteers); each row corresponds to a gene (n = 190) that was found to differ between two or more groups
of cultures with individual drugs. The columns are labelled at the bottom according to patient number (1–4) and antibiotic in the culture (by first
letter). The antibiotic in each assay is also shown by the colour coding at the top of the column, clearly demonstrating that there is perfect
clustering by antibiotic used. Clusters of genes with identifiable pathways are shown as “M” (cell membrane or transmembrane processes; 17
genes), “N” (nucleotide binding, ATP binding, and lipid metabolism; 93 genes); “O” (oxidoreductase; 51 genes)
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response to isoniazid alone in TB macrophage culture
versus broth culture found only 40% overlap [4].
Whether the theoretical advantages of the WBA model
outlined above carry any advantages for gene expression
profiling over simpler culture methods will need further
study.
The finding that the transcriptome profile achieved
separation between individual anti-TB drugs indicatesthat it is responding uniquely to the drug environment
in the whole blood assay and this may represent a useful
new indicator of activity in this assay paradigm. This
unique expression was present even for moxifloxacin
that appeared to have limited activity at the first hour of
incubation, and for pyrazinamide, ethambutol, and faro-
penem, which appeared to have minimal detectable bac-
tericidal activity even during the full 72-h incubation
period of the assay. The limited bactericidal activity of
Fig. 3 Numbers of differentially expressed genes in the overall drug-related gene expression profile (in parentheses after drug name) and in the
unique drug-related gene expression profile (in circles within the set for each drug)
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digm; for pyrazinamide it may perhaps reflect the requirement
for a hypoxic environment for activity [8, 11, 21, 22]; for faro-
penem it may reflect rapid degradation of the drug in whole
blood during the course of incubation or that higher doses are
needed for activity [9]. The adaptation of the WBA model to
provide a readout of transcriptome change rather than a read-
out of bactericidal activity may in part overcome the limita-
tions of the traditional WBA assay for detecting drug activity.
A study analyzing transcriptomics with 74 novel or known
antibacterial agents in broth cultures also demonstrated clear
differences between drugs of similar classes [3]. Several stud-
ies have suggested that using a minimal number of Mtb
genes in such an approach might facilitate routine drug
high throughput screening [5, 23]. We included farope-
nem, a non-standard TB drug, in this study because previ-
ous data showing minimal activity of this drug in a WBA
assay [9], contrasts with the substantial body of emerging
data on the value of beta-lactams for anti-TB treatmentin vivo [24, 25]. However, there is no certainty that the de-
tection of a change in bacterial transcriptome, with faro-
penem or any other drug, would necessarily translate into
substantive bactericidal or sterilizing activity in vivo.
Although we found some associations between the
gene clusters and pathways known to be relevant to ac-
tion of one or more of the antibiotics investigated, we
found only limited evidence that the whole blood tran-
scriptome model could identify the specific mechanism
of action of anti-TB drugs (with the exception of isonia-
zid, where we found evidence of characteristic pathways
as previously shown in broth cultures [3], and in micro-
array studies that have demonstrated isoniazid-specific
gene responses from the fatty acid synthesis II (FAS-II)
and mycolic acid synthesis-related pathways) [26, 27].
The limited ability of this assay to detect gene expres-
sion changes related to known mechanisms of action of
the individual drugs may reflect differences in the mech-
anism of action according to the environment to which
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changes were seen in a previous study with drug expos-
ure in broth cultures [3], and it is possible that the add-
itional presence of immune cells in the WBA paradigm
modifies the response to drugs. We have demonstrated
that neutrophils significantly alter the bactericidal activ-
ity of rifampicin in the WBA paradigm, possibly by
intracellular bacterial sequestration [28]. In an ex vivo
cellular model, the response to drugs was more charac-
teristic of host responses than of specific effects on the
primary drug targets [4].
One of the limitations of our adapted model is that we
standardized to a single (1-h) incubation time. The dur-
ation of the incubation period is likely of paramount im-
portance, as there needs to be sufficient time for the
drug to have an influence on bacterial gene expression
whilst not allowing for prolonged exposure and signifi-
cant bacterial killing that might reduce the amount of
bacterial RNA below a critical threshold for analysis (our
blood volumes per assay were relatively small and
already at or close to the threshold for RNA detection).
The optimal time could differ between drugs, but we
preferred to standardize to a single incubation time so
that other factors that might influence gene expression
in the assay (for instance immune-mediated bacterial
killing) would be better controlled to enable us to com-
pare more directly the transcriptome changes associated
with the individual drugs. From a practical perspective,
we also wanted to develop a standardized assay para-
digm that might easily be translated to testing future
drugs, without requiring the cumbersome step of per-
forming multiple time-kill curves to optimize the para-
digm prior to testing a new drug. Performing repeated
transcriptome analysis at multiple incubation timepoints
for each drug would be practically (volume of blood re-
quired for assays) and economically infeasible. It is pos-
sible that the absence of signature transcriptome
changes that align directly with known mechanism of ac-
tions of the drugs (except for isoniazid) arises from inad-
equate exposure time to these less cidal drugs and that
we might have seen more characteristic changes with a
longer incubation period. Nevertheless, we found
uniquely expressed genes for each of the drugs, which
indicates that the exposure was long enough for the bac-
teria to recognize and respond to the drug challenge.
Conclusions
In summary, we have shown that an alternative readout
– change in bacterial transcriptome – can be obtained
from an adapted WBA paradigm and that this responds
in a similar way to the bacterial transcriptome in sputum
when exposed to standard 4-drug combination therapy.
The method detects gene expression responses to anti-
tuberculosis drugs, even to drugs that show no overtbacterial killing in the WBA assay. However, the adapted
method may have limited value in identifying pathways
associated with the mechanism of action of individual
drugs, although this may perhaps be overcome with fur-
ther modifications to the assay such as drug-specific in-
cubation times which remain to be explored.
Methods
Drug bactericidal curves in the whole blood assay
Initial experiments were performed to determine the
bactericidal curves of individual drugs for the purposes
of selecting a standard time point for later transcrip-
tomic studies. For these studies, 50 ml of whole blood
was drawn into heparin tubes from each of three healthy
(without current acute or chronic illness) adult
volunteers.
The whole blood assay was performed and calculated
as previously described [22]. Briefly, the Mtb H37Rv lab
strain was grown in 7H9 medium containing 0.2% gly-
cerol, 0.05% tween 80 and ADC supplement (sodium
chloride, Bovine Serum Albumin Fraction V, anhydrous
Dextrose and Catalase) to mid-log phase, and aliquots
were taken and frozen in glycerol at − 80 °C. Volumes of
this stock were then serially diluted and each inoculated
into a Mycobacteria Growth Indicator Tube (MGIT)
tubes to determine the relationship between inoculum
volume and time-to-positivity (TTP). The specific vol-
ume of stock that gave a TTP of 5.5 days was identified
(containing ~ 105 CFU/ml) and this was used as the
standard inoculum in all experiments.
Whole-blood cultures were prepared by mixing 300ul
heparinized blood with one of the study drugs and made
up to a total volume of 600ul by adding RPMI 1640 cul-
ture medium with 25 mmol/L N-2-hydroxyethylpipera-
zine-N′-2 ethane sulfonic acid). These were incubated
for 30 min at room temperature. Study drug was then
added in the amount required to achieve a final concen-
tration based on the published values of Cmax in phar-
macokinetic studies performed with standard clinical
doses: rifampicin 10 μg/ml [29, 30]; isoniazid 5 μg/ml
[29]; pyrazinamide 25 μg/ml [29]; ethambutol 5 μg/ml
[29]; moxifloxacin 4 μg/ml [29, 31, 32]; and faropenem
sodium (Farobact, Cipla, Mumbai), amoxicillin and cla-
vulanic acid (5, 10, and 3 μg/ml respectively). Eight sep-
arate cultures were set-up with individual rifampicin,
isoniazid, pyrazinamide, ethambutol and moxifloxacin;
faropenem (with amoxicillin and clavulanic acid); the
combination of rifampicin, isoniazid, pyrazinamide and
ethambutol; and a drug-free control culture with 0.9%
dimethyl sulfoxide added (DMSO; control for the pur-
pose of comparing the bactericidal curves). The standard
volume of Mtb stock (identified as above), was added to
all cultures and incubated at 37 °C with slow constant
mixing. From each of the three 50ml blood samples,
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8 drug conditions, each in duplicate).
At pre-specified Mtb incubation time-points (0.5, 1,
1.5, 2, 4, 6, 24, 48, 72 h), duplicate cultures were centri-
fuged; blood cells lysed, pellets washed; and resuspended
into mycobacterial growth inhibition tubes (MGITs) and
incubated using the MGIT960 system (Becton Dickin-
son, Franklin Lakes, USA). The time to positivity (TTP)
was recorded. Control cultures (for WBA calculations)
were set-up by inoculating the standard volume of Mtb
stock into MGIT tubes on the same day as the prepar-
ation of whole blood cultures.
The WBA for the samples obtained for individual drug/
incubation times was calculated from the difference be-
tween the log of the volume on the standard curve that
corresponded to the TTP for that sample and log of the
volume corresponding to the TTP of the control culture.
This is equivalent to the difference in log of bacterial col-
onies forming units (CFU) between the sample and the
control, reported as Δ log CFU. Drugs with higher bacteri-
cidal activity have a larger change in log CFU over time
(lower negative values), whereas drugs with little or no ac-
tivity (bacteriostatic) have values close to zero.
An incubation time of 1 h was selected for the subse-
quent experiments based on the average time needed to
reduce the initial inoculum by one log CFU in blood cul-
tures containing isoniazid and rifampicin (approximately
0.5 and 1.5 h respectively), with the assumption that this
would give sufficient time for drugs to demonstrate ef-
fects on gene expression whilst minimizing the reduc-
tion of viable cells.
Gene expression profiling from the whole blood cultures
A 70ml sample of whole blood was drawn from each of
4 healthy volunteers who had no history of chronic dis-
ease, no history of TB and who had a negative IGRA.
WBA cultures were set-up as described above, but with
a 25-fold increase in volumes (to a total volume of 15ml
blood culture) whilst maintaining the ratios of blood and
TB inoculum and the drug concentration unchanged. Cul-
tures for the same eight drug/control conditions as de-
scribed above were prepared in quadruplicate (each
replicate assay prepared separately from the blood of one
of the four healthy volunteers) and were incubated for 1 h
(time selected from the kill curves, as above).
RNA was extracted from 15ml whole blood cultures
by adding Guanidium Thiocyanate solution for host cell
lysis, followed by resuspension of cells in 1 ml TRIzol
Reagent (Thermo Fisher Scientific, Massachusetts, USA)
for Mtb inactivation, Mtb cells were mechanically lyzed
using the FastPrep 24 Tissue Homogenizer (MP Bio-
medicals, California, USA) at 4x30s, 6.0 m/s followed by
phenol-chloroform steps outlined in the TRIzol user
manual. Samples were treated with DNAse-I usingTURBO DNA-free kit (Thermo Fisher Scientific, Massa-
chusetts, USA).
Gene expression profiling from broth cultures
The Mtb H37Rv lab strain was grown (O.D.0.5–0.7) as
described above, were centrifuged, washed with RNA-
protect Cell Reagent (Qiagen, Hilden, Germany) and re-
suspended with TRIzol Reagent. RNA was extracted
from the sputum samples using the same approach as
whole blood cultures.
Gene expression profiling from sputum
A single sputum sample was collected from each of 9
adult patients with drug-susceptible pulmonary TB, who
were HIV-negative and without other serious chronic
diseases. All cases were confirmed by culture and iso-
lates were demonstrated to be susceptible to strepto-
mycin, isoniazid, rifampicin and ethambutol. Five of the
patients had cavitation on chest X-ray. Patients had re-
ceived a mean of 9 ± 4 days standard anti-tuberculous
chemotherapy (rifampicin, isoniazid, pyrazinamide and
ethambutol) at the time the sputum sample was ob-
tained. RNA was extracted from the sputum samples
using the same approach as whole blood cultures.
Microarray and functional annotation
Total RNA yield was quantified using Bioanalyzer (Agi-
lent Technologies, California, USA) and the presence of
Mtb RNA was verified by RT-qPCR using Taqman
probes and primers targeting mycobacteria species’ 16 s
ribosomal RNA (primer sequences obtained from a pre-
vious study) [33]. The RNA samples were prepared for
microarray hybridization using the Affymetrix 3′ Pico
IVT sample preparation kit (Thermo Scientific, Massa-
chusetts, USA).
Microarray signals were generated using a custom
Affymetrix Mtb chip (MTubEX1; Thermofisher scien-
tific, Massachusetts, USA) that was designed with signal
processing algorithms specific for Mtb H37Rv genes and
read using GeneChip® Scanner. Signal processing and
normalization was done by Robust Multiarray Analysis
(RMA) [34, 35], performed using R software package
Affy and Affycoretools.
The overall workflow is depicted in Fig. 1. Analyses of
differentially-expressed genes (DEG) in whole blood cul-
tures incubated with the standard rifampicin, isoniazid,
pyrazinamide and ethambutol combination and in the
sputum of patients taking the same combination (each
relative to broth cultures) was performed using the R
package Limma [36] (cut-off of log fold change > 2 in ei-
ther direction and False Discovery Rate < 0.05 by the
Benjamini-Hochberg procedure) [36, 37]. The overlap in
DEG between blood culture and sputum was tested for
significance by the exact hypergeometric probability
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established pathways for treatment response in TB, as
reported in an earlier study [1, 2].
Gene expression profiles were compared between individ-
ual drugs (faropenem counted as an individual drug, al-
though tested in whole blood cultures with amoxicillin and
clavulanate for synergy), by applying one-way analysis of vari-
ance (ANOVA) to the normalized genes (without removing
genes that were differentially expressed in DMSO control
cultures versus broth culture) to select genes that differed
(p < 0.05) between two or more drug-culture groups (each
group comprising 4 cultures with an individual drug). Hier-
archical clustering was performed based on these selected
genes using Euclidean distance and complete linkage, initially
based on the gene profiles in individual cultures and subse-
quently based on individual genes and results were plotted
as a heatmap. Pathway enrichment was performed for the
gene clusters using Database for Annotation, Visualization
and Integrated Discovery (DAVID) software [38]. Clustering
analysis was done on the individual cultures samples via
pvclust R software package using Approximately Unbiased
(AU) p values by bootstrapping methods to evaluate individ-
ual dendrograms (≥95% for significant clusters) [39].
The overall drug-related gene expression profile for each in-
dividual drug was determined by identifying genes in whole
blood culture that were differentially expressed relative to
broth culture for that drug and then removing genes that
were also differentially expressed (versus broth culture) in
the control cultures with DMSO using the same FDR cut-
offs as above. The unique drug-related gene expression profile
for each of the individual drugs was determined by removing
genes that were found in the overall drug-related gene ex-
pression profiles of any of the other individual drugs.
The functional aspects of the gene expression profiles
were explored by applying pathway enrichment analysis
on the overall and unique drug-related gene expression
profiles using DAVID software, applying a modified
Fisher Exact P-value < 0.05 to identify significant path-
ways. Annotation of genes was performed using Gene
Ontology (GO) database. All analyses were done using
in-house python or R software scripts.
The study protocols received ethics approval from the
Domain Specific Review Board of the National Health-
care Group, Singapore.
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